Oseltamivir
Oseltamivir, Oseltamivir Phosphate, Tamiflu
NADAC/unit
$0.1497
No Shortage
Tier 1: 95.1%
26 Manufacturers
68 ANDAs
Oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who h....
vs. brand Oseltamivir: Generic saves up to 99% per unit
Active Shortages
2025-09-30 Discontinuation of the manufacture of the drug, Genentech, Inc
2025-07-08 Discontinuation of the manufacture of the drug, Genentech, Inc
Market Intelligence
2024-02-28 Class II Recall: Amneal Pharmaceuticals of New York, LLC
Generic Manufacturers
AJANTA PHARMA LTDALEMBIC PHARMACEUTICALS LTDALVOGEN INCAMNEAL PHARMACEUTICALS OF NEW YORK LLCAMNEAL PHARMACEUTICALS OF NY LLCAUROBINDO PHARMA LTDBEIJING JIALIN PHARMACEUTICAL CO LTDCEDIPROF INCEPIC PHARMA LLCHETERO LABS LTD UNIT IIIHETERO LABS LTD UNIT VHOFFMANN LA ROCHE INCINVAGEN PHARMACEUTICALS INCJUBILANT GENERICS LTDLAURUS LABS LTDLUPIN INCMACLEODS PHARMACEUTICALS LTDMSN LABORATORIES PRIVATE LTDNATCO PHARMA LTDPHARMOBEDIENT CONSULTING LLCSHANDONG NEW TIME PHARMACEUTICAL CO LTDSTRIDES PHARMA GLOBAL PTE LTDSUNSHINE LAKE PHARMA CO LTDTEVA PHARMACEUTICALS USA INCUPSHER SMITH LABORATORIES LLCZHEJIANG POLY PHARM CO LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.